AstraZeneca Additional Paid In Capital from 2010 to 2024
| AZN Stock | USD 63.39 0.16 0.25% |
Additional Paid In Capital | First Reported 2010-12-31 | Previous Quarter 35.3 B | Current Value 37.1 B | Quarterly Volatility 14.2 B |
Check AstraZeneca PLC financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among AstraZeneca PLC's main balance sheet or income statement drivers, such as Depreciation And Amortization of 5.2 B, Interest Expense of 1.7 B or Total Revenue of 24.2 B, as well as many indicators such as Price To Sales Ratio of 2.62, Dividend Yield of 0.0285 or PTB Ratio of 9.53. AstraZeneca financial statements analysis is a perfect complement when working with AstraZeneca PLC Valuation or Volatility modules.
AstraZeneca | Additional Paid In Capital |
Latest AstraZeneca PLC's Additional Paid In Capital Growth Pattern
Below is the plot of the Additional Paid In Capital of AstraZeneca PLC ADR over the last few years. Additional Paid In Capital (or APIC) is an accounting term found on AstraZeneca PLC ADR Balance Sheet under Shareholders Equity. It is the value of the shares of the company above what they were issued it. The basic calculation is as follow: (Issue Price - Par Value) x AstraZeneca PLC Shares Outstanding. Additional Paid In Capital is not affected by secondary trading of AstraZeneca PLC ADR shares and does not have any impact on the value of APIC. It is the excess amount paid by investors over the par value of a company's shares, representing the additional capital contributed by shareholders. AstraZeneca PLC's Additional Paid In Capital historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in AstraZeneca PLC's overall financial position and show how it may be relating to other accounts over time.
| Additional Paid In Capital | 10 Years Trend |
|
Additional Paid In Capital |
| Timeline |
AstraZeneca Additional Paid In Capital Regression Statistics
| Arithmetic Mean | 13,124,136,667 | |
| Geometric Mean | 8,069,863,871 | |
| Coefficient Of Variation | 108.21 | |
| Mean Deviation | 12,071,933,778 | |
| Median | 4,546,000,000 | |
| Standard Deviation | 14,201,680,847 | |
| Sample Variance | 201687738.9T | |
| Range | 33.5B | |
| R-Value | 0.82 | |
| Mean Square Error | 72573215.9T | |
| R-Squared | 0.67 | |
| Significance | 0.0002 | |
| Slope | 2,591,315,536 | |
| Total Sum of Squares | 2823628344.1T |
AstraZeneca Additional Paid In Capital History
About AstraZeneca PLC Financial Statements
AstraZeneca PLC investors utilize fundamental indicators, such as Additional Paid In Capital, to predict how AstraZeneca Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Additional Paid In Capital | 35.3 B | 37.1 B |
Pair Trading with AstraZeneca PLC
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if AstraZeneca PLC position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in AstraZeneca PLC will appreciate offsetting losses from the drop in the long position's value.Moving together with AstraZeneca Stock
| 0.85 | VALN | Valneva SE ADR | PairCorr |
| 0.67 | DYAI | Dyadic International | PairCorr |
| 0.76 | ERNA | Eterna Therapeutics | PairCorr |
Moving against AstraZeneca Stock
| 0.74 | LPCN | Lipocine | PairCorr |
| 0.65 | WAT | Waters | PairCorr |
| 0.63 | MNMD | Mind Medicine | PairCorr |
| 0.44 | GNFT | Genfit | PairCorr |
| 0.35 | INBX | Inhibrx Symbol Change | PairCorr |
The ability to find closely correlated positions to AstraZeneca PLC could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace AstraZeneca PLC when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back AstraZeneca PLC - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling AstraZeneca PLC ADR to buy it.
The correlation of AstraZeneca PLC is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as AstraZeneca PLC moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if AstraZeneca PLC ADR moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for AstraZeneca PLC can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out the analysis of AstraZeneca PLC Correlation against competitors. You can also try the Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of AstraZeneca PLC. If investors know AstraZeneca will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about AstraZeneca PLC listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.034 | Dividend Share 2.97 | Earnings Share 2.07 | Revenue Per Share 2.7424 | Quarterly Revenue Growth 0.18 |
The market value of AstraZeneca PLC ADR is measured differently than its book value, which is the value of AstraZeneca that is recorded on the company's balance sheet. Investors also form their own opinion of AstraZeneca PLC's value that differs from its market value or its book value, called intrinsic value, which is AstraZeneca PLC's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because AstraZeneca PLC's market value can be influenced by many factors that don't directly affect AstraZeneca PLC's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between AstraZeneca PLC's value and its price as these two are different measures arrived at by different means. Investors typically determine if AstraZeneca PLC is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, AstraZeneca PLC's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.